Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer
Y Iizuka, T Katagiri, K Ogura, T Mizowaki - Annals of Nuclear Medicine, 2019 - Springer
Objective This study aimed to compare the clinical outcomes of patients who received
radioactive iodine (RAI) ablation after undergoing thyroidectomy for intermediate-to-high-risk …
radioactive iodine (RAI) ablation after undergoing thyroidectomy for intermediate-to-high-risk …
A retrospective cohort study with validation of predictors of differentiated thyroid cancer outcomes
Background: The goal of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) is to
treat metastasis and reduce recurrence risk. International guidelines provide broad risk …
treat metastasis and reduce recurrence risk. International guidelines provide broad risk …
Radioiodine versus no radioiodine outcomes in low‐risk differentiated thyroid cancers: A propensity‐score matched analysis
S Satapathy, A Tupalli, KR Chandekar… - Clinical …, 2023 - Wiley Online Library
Abstract Objective The 2015 American Thyroid Association guidelines recommend against
radioiodine (RAI) ablation for patients with low‐risk papillary microcarcinoma. However, its …
radioiodine (RAI) ablation for patients with low‐risk papillary microcarcinoma. However, its …
Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma
J Mihailović - Journal of Clinical Medicine, 2024 - mdpi.com
Radioiodine imaging in initial perioperative settings, after the total thyroidectomy, includes
pre-treatment and post-treatment radioiodine imaging. While the benefit of post-treatment …
pre-treatment and post-treatment radioiodine imaging. While the benefit of post-treatment …
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study
Y Liu, Y Wang, W Zhang - EJNMMI research, 2022 - Springer
Background Differentiated thyroid carcinoma (DTC) originates from abnormal follicular cells
and accounts for approximately 90–95% of thyroid malignancies. The diagnosis of …
and accounts for approximately 90–95% of thyroid malignancies. The diagnosis of …
Post-Surgical Indications to Radioiodine Treatment and Potential Risk Factors for Post-Treatment Recurrence in Patients with Intermediate-Risk Differentiated Thyroid …
In this multicentric retrospective observational study, we investigated the potential risk
factors for radioiodine (RAI) indication and the post-treatment recurrence of intermediate-risk …
factors for radioiodine (RAI) indication and the post-treatment recurrence of intermediate-risk …
A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of …
R Wen, M Zhao, C Chen, Y Yang, B Zhang - Endocrine, 2024 - Springer
Purpose To investigate the factors influencing the outcome of radioactive iodine (RAI)
treatment in intermediate-to high-risk patients with differentiated thyroid carcinoma (DTC) …
treatment in intermediate-to high-risk patients with differentiated thyroid carcinoma (DTC) …
Postablation 131I scintigraphy with neck and thorax SPECT–CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid …
R Ciappuccini, N Heutte, G Trzepla… - European journal of …, 2011 - academic.oup.com
Objective Neck and thorax single photon emission computed tomography with computed
tomography (SPECT–CT) improves the reliability of postablation 131I whole-body scan …
tomography (SPECT–CT) improves the reliability of postablation 131I whole-body scan …
Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer
JH Jeong, EJ Kong, SY Jeong, SW Lee… - Nuclear medicine …, 2017 - journals.lww.com
Purpose Recent studies have suggested that a low dose (LD) of radioiodine (RAI) is
sufficient to treat differentiated thyroid cancer (DTC) even in patients with intermediate risk …
sufficient to treat differentiated thyroid cancer (DTC) even in patients with intermediate risk …
Long-term follow-up of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment
LSC Caminha, DP Momesso, F Vaisman… - Clinical Nuclear …, 2013 - journals.lww.com
Results During mean follow-up of 13.7±4.2 years, 20% of patients developed recurrence. At
the end of follow-up, 21% of patients had persistent disease. The clinical and histological …
the end of follow-up, 21% of patients had persistent disease. The clinical and histological …